AVEO Oncology (NASDAQ: AVEO) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014.
Management plans to host financial results conference calls on a semi-annual basis, with the Company’s next conference call in August 2014. At that time, the Company will review its mid-year financial results and provide an update on its corporate strategy. In the interim, AVEO continues to welcome communications from shareholders throughout the year as the Company seeks to continue to execute against its 2014 strategic plan and objectives.
Further details about the Company’s business and financial results will be available in a Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission after Q1 financial results are released.
AVEO Oncology (NASDAQ: AVEO) is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform
provides the company with unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. For more information, please visit the company’s website at